Ainhoa Larrañaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ainhoa Larrañaga has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Albert Álvarez-Muñoz
Metabolic Dynamics in Cancer Laboratory, Department of Cell Biology, Physiology and Immunology, School of Biology, Universitat de Barcelona (UB), Parc Científic de Barcelona; 08028 Barcelona, Spain
1 shared publication- Alessia Mira
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino 10126, Italy
1 shared publication - Andrea Bonilla-Díaz
Metabolic Dynamics in Cancer Laboratory, Department of Cell Biology, Physiology and Immunology, School of Biology, Universitat de Barcelona (UB), Parc Científic de Barcelona; 08028 Barcelona, Spain
1 shared publication - Anna Esteve-Codina
Centro Nacional de Analisis Genomico (CNAG)
1 shared publication - Anna Sapino
INOC - Istituto Nazionale Oncologico Candiolo; IRCCS, Candiolo, Italy
1 shared publication - Carlos Sebastián
Metabolic Dynamics in Cancer Laboratory, Department of Cell Biology, Physiology and Immunology, School of Biology, Universitat de Barcelona (UB), Parc Científic de Barcelona; 08028 Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
Pdk1-dependent metabolic heterogeneity promotes aggressive colorectal cancer through cell-intrinsic interferon signaling
Tumor heterogeneity is a major determinant of tumor progression and therapeutic resistance, yet the contribution of metabolism to intratumoral heterogeneity still remains poorly explored. Here, we find that pyruvate dehydrogenase kinase-1 (Pdk1) expression defines metabolically distinct cancer cell populations in colorectal tumors. Image-based spatial single-cell phenotyping shows that Pdk1 high cells are associated with tumor progression in orthotopic models of colorectal cancer (CRC). Genetic ablation experiments demonstrate the role of Pdk1 high cells in tumor growth, 5-fluorouracil chemoresistance and tumor relapse. Mechanistically, we identify a link between Pdk1-driven metabolic states and specific cell phenotypes, where Pdk1 high cancer cells exhibit an EMT, stem cell-like phenotype characterized by increased interferon (IFN) signaling. Mitochondrial remodeling in Pdk1 high cells leads to the release of mitochondrial DNA to the cytosol and activation of IFN pathways, promoting Pdk1-driven phenotypes. Inhibition of IFN signaling impairs the tumorigenic and aggressive features of Pdk1 high cancer cells, thus establishing a functional connection between metabolic heterogeneity, cell-intrinsic IFN signaling and aggressive CRC.
Open AccessPdk1-dependent metabolic heterogeneity promotes aggressive colorectal cancer through cell-intrinsic interferon signaling
Tumor heterogeneity is a major determinant of tumor progression and therapeutic resistance, yet the contribution of metabolism to intratumoral heterogeneity still remains poorly explored. Here, we find that pyruvate dehydrogenase kinase-1 (Pdk1) expression defines metabolically distinct cancer cell populations in colorectal tumors. Image-based spatial single-cell phenotyping shows that Pdk1 high cells are associated with tumor progression in orthotopic models of colorectal cancer (CRC). Genetic ablation experiments demonstrate the role of Pdk1 high cells in tumor growth, 5-fluorouracil chemoresistance and tumor relapse. Mechanistically, we identify a link between Pdk1-driven metabolic states and specific cell phenotypes, where Pdk1 high cancer cells exhibit an EMT, stem cell-like phenotype characterized by increased interferon (IFN) signaling. Mitochondrial remodeling in Pdk1 high cells leads to the release of mitochondrial DNA to the cytosol and activation of IFN pathways, promoting Pdk1-driven phenotypes. Inhibition of IFN signaling impairs the tumorigenic and aggressive features of Pdk1 high cancer cells, thus establishing a functional connection between metabolic heterogeneity, cell-intrinsic IFN signaling and aggressive CRC.